Status:
UNKNOWN
Low Dose Radiotherapy in COVID-19 Pneumonia
Lead Sponsor:
Shahid Beheshti University of Medical Sciences
Conditions:
COVID
SARS (Severe Acute Respiratory Syndrome)
Eligibility:
All Genders
60+ years
Phase:
PHASE1
PHASE2
Brief Summary
Moderate to severe cases of SARS-associated ARDS based on inclusion/ exclusion criteria and the decision made in multi- disciplinary team are treated with 0.5 Gy whole lung radiation.
Detailed Description
SARS-associated ARDS (acute respiratory distress syndrome) is the most fatal outcome of COVID-19 systemic infection. To overcome the uncontrolled inflammation leading to ARDS and respiratory failure, ...
Eligibility Criteria
Inclusion
- Confirmed COVID-19 diagnosis ( PCR or serologic or radiographic)
- Presence of pulmonary involvement ( defined by P/F ratio or NIV need)
- Less than 3 days since the onset of ARDS
- Age \> 60 years
- ↑ IL-6 ( if available)
- ↑ CRP
Exclusion
- Lack of informed consent
- Inability to transfer to the radiation unit
- Hemodynamic instability
- Septic shock and organ dysfunction
- Severe ARDS P/F ratio ≤ 100 mmHg
- History of cardiac failure
- Contraindications to radiation
Key Trial Info
Start Date :
May 4 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2020
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT04390412
Start Date
May 4 2020
End Date
December 1 2020
Last Update
November 10 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Imam Hossein Hospital
Tehran, Iran